Trial Profile
Phase I trial of sublingual apomorphine in patients with Parkinson's disease.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2011
Price :
$35
*
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Amarin Corporation
- 27 Jun 2011 Status changed from planning to discontinued prior to enrolment.
- 26 Nov 2007 New trial record.